Pharmaceutical - Johnson & Johnson


Current filters:

Johnson & Johnson

Popular Filters

226 to 242 of 242 results

US FDA advisory panel votes against added indication for Bayer's Xarelto


Despite relatively positive briefing papers earlier this week (The Pharma Letter May 22), the US Food…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

FDA staffers basically back Xarelto for ACS but identify missing data in study


The US Food and Drug Administration advisory panelists due to revue Johnson & Johnson (NYSE: JNJ) and…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Positive Ph III results for J&J's Nucynta in diabetic peripheral neuropathy


Janssen Pharmaceuticals, a unit of health care major Johnson & Johnson yesterday announced the results…

DiabetesJanssenJohnson & JohnsonNeurologicalNucyntaPharmaceuticalResearch

UK's NICE does U-turn, recommending Zytiga as Janssen cuts price


UK drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has reversed an earlier…

EuropeJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

Furiex Pharma gets rights to Priligy, some of which it sells on to Menarini


In a two part transaction, USA-based Furiex Pharmaceuticals (Nasdaq: FURX) has entered into an agreement…

ALZA CorpFuriex PharmaceuticalsJanssen PharmaceuticaJohnson & JohnsonLicensingMen's HealthMenariniPharmaceuticalPriligy

UK academia-pharma collaboration attracts £14.4 million funding


In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

EU Commission OKs J&J's buy of Synthes, but with conditions


The European Commission last week cleared under the EU Merger Regulation the proposed $21.3 billion acquisition…

Johnson & JohnsonMergers & AcquisitionsPharmaceuticalSynthes

Bristol-Myers expands hepatitis C accord with Medivir and Janssen


Swedish infectious disease drug developer Medivir AB (OMX: MVIR) said yesterday that its development…

Anti-viralsBristol-Myers SquibbdaclatasvirJanssenJohnson & JohnsonLicensingMedivirPharmaceuticalResearch

Johnson & Johnson 1st-qtr earnings up 12.5% but sales flat


US health care giant Johnson & Johnson (NYSE: JNJ) posted first-quarter 2012 financial results in line…

FinancialJohnson & JohnsonPharmaceutical

News briefs on Janssen, Bayer and Merck KGaA/Threshold


In the USA, the Arkansas jury found that the Janssen unit of US health care giant Johnson & Johnson (NYSE:…

BayerFinancialJanssenJohnson & JohnsonLegalMerck KGaAPharmaceuticalRegulationRisperdalThreshold PharmaceuticalsXarelto

Senior exec changes actual or sought at Johnson & Johnson, AstraZeneca and Optimer


US health care giant Johnson & Johnson (NYSE: JNJ) said on Monday that Sherilyn (Sheri) McCoy, vice chairman…

AstraZenecaJohnson & JohnsonManagementOptimer PharmaceuticalsPharmaceutical

Forest Labs buys Bystolic rights from Janssen for $357 million


Forest Laboratories, (NYSE: FRX) says it has acquired all US patents and other US and Canadian intellectual…

BystolicCardio-vascularForest LaboratoriesJanssen PharmaceuticaJohnson & JohnsonLicensingNorth AmericaPharmaceuticalSavella

Strong results for Bayer's Xarelto in treating pulmonary blood clots


German drugs and crops sciences group Bayer (BAY: DE), and partner Janssen, part of US health care major…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalRegulationResearchRespiratory and PulmonaryXarelto

226 to 242 of 242 results

Back to top